BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/14/2021 9:21:56 AM | Browse: 397 | Download: 792
 |
Received |
|
2021-01-31 11:50 |
|
Peer-Review Started |
|
2021-01-31 12:16 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-15 12:40 |
|
Revised |
|
2021-03-16 15:23 |
|
Second Decision |
|
2021-03-24 08:08 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-03-24 17:48 |
|
Articles in Press |
|
2021-03-24 17:48 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-04-04 10:44 |
|
Typeset the Manuscript |
|
2021-05-10 09:22 |
|
Publish the Manuscript Online |
|
2021-05-14 09:21 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li-Fang Bian, Chao Zheng and Xiao-Lan Shi |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical Health Science and Technology Project of Zhejiang Provincial Health Commission, China |
2020372769 |
|
| Corresponding Author |
Li-Fang Bian, MSN, Associate Chief Nurse, Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qing Chun Road, Hangzhou 310003, Zhejiang Province, China. doggie_cc@zju.edu.cn |
| Key Words |
Atezolizumab; Immune checkpoint inhibitors; Anaphylactic shock; Hypersensitivity reaction; Infusion reaction; Hepatocellular carcinoma; Case report |
| Core Tip |
Treatment with immune checkpoint inhibitors (ICIs) can lead to hypersensitivity reactions; however, anaphylactic shock is rare. We present a case of life-threatening anaphylactic shock during atezolizumab infusion and a relevant literature review. Patients may be allergic to drugs targeting both programmed death-1 (PD-1) and programmed death ligand 1 (PD-L1). Adequate attention should be paid to the related complications in the use of immune checkpoint inhibitors. Nevertheless, further studies are needed to understand the underlying mechanisms of hypersensitivity reactions and establish standardized skin test and desensitization protocols associated with PD-1 and PD-L1 to ensure effective treatment with ICIs. |
| Publish Date |
2021-05-14 09:21 |
| Citation |
Bian LF, Zheng C, Shi XL. Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report. World J Clin Cases 2021; 9(16): 4110-4115 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i16/4110.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i16.4110 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
